Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer AB (EP2507255) Provided are peptides that bind to the thymidylate synthase protein, in particular to human thymidylate synthase (hTS) protein, for the treatment of cancer. Further provided are peptides that can bind at a binding site located at the interface of thymidylate synthase protein. These peptides range from 3 to 10, preferably 4-8 amino acids and have a sequence that binds to each subunit of the thymidylate synthase dimer at the level of dimer interface, stabilizing the dimeric inactive form of the thymidylate synthase enzyme. In addition, provided are pharmaceutical compositions including these compounds as active agents, and uses thereof for the treatment of cancer and to reverse or/and be active in cancer drug resistance. (From US8916679 B2)

Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer-US8916679 “B2 - Granted patent as second publication” / Costi, Maria Paola; Marverti, Gaetano; Cardinale, Daniela; Venturelli, Alberto; Ferrari, Stefania; Ponterini, Glauco. - (2014).

Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer-US8916679 “B2 - Granted patent as second publication”.

COSTI, Maria Paola;MARVERTI, Gaetano;CARDINALE, Daniela;VENTURELLI, Alberto;FERRARI, Stefania;PONTERINI, Glauco
2014

Abstract

Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer AB (EP2507255) Provided are peptides that bind to the thymidylate synthase protein, in particular to human thymidylate synthase (hTS) protein, for the treatment of cancer. Further provided are peptides that can bind at a binding site located at the interface of thymidylate synthase protein. These peptides range from 3 to 10, preferably 4-8 amino acids and have a sequence that binds to each subunit of the thymidylate synthase dimer at the level of dimer interface, stabilizing the dimeric inactive form of the thymidylate synthase enzyme. In addition, provided are pharmaceutical compositions including these compounds as active agents, and uses thereof for the treatment of cancer and to reverse or/and be active in cancer drug resistance. (From US8916679 B2)
2014
UNIMORE and HITS (Heidelberg)(DE)
US8916679
Costi, Maria Paola; Marverti, Gaetano; Cardinale, Daniela; Venturelli, Alberto; Ferrari, Stefania; Ponterini, Glauco
File in questo prodotto:
File Dimensione Formato  
PatentUS8916679.pdf

accesso aperto

Descrizione: Descrizione relativi ai dettagli tecnici del brevetto US concesso.
Tipologia: Altro materiale allegato
Dimensione 108.7 kB
Formato Adobe PDF
108.7 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1061973
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact